Aditya Bardia, MD, MPH

Articles

Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

July 8th 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

July 8th 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Dr Bardia on the Limitations of HER2 Testing Assays in HER2-Low and -Ultralow Breast Cancer

July 2nd 2024

Aditya Bardia, MD, MPH, FASCO, discusses HER2 IHC testing in patients with HER2-low and -ultralow metastatic breast cancer.

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

July 1st 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Preoperative Monitoring and Surgical Options for HER2+ Patients

July 1st 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

June 25th 2024

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.

Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

June 24th 2024

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

Challenges in Diagnosing HER2+ Breast Cancer

June 24th 2024

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

Dr Bardia on Current Approaches to HER2+ Breast Cancer Management

June 19th 2024

Aditya Bardia, MD, MPH, FASCO, discusses standard first-, second-, and third-line HER2-positive metastatic breast cancer management approaches.

Dr Bardia on the Efficacy and Safety of Dato-DXd in HR+/HER2– Breast Cancer

December 15th 2023

Aditya Bardia, MD, MPH, discusses key efficacy results from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

Dr Bardia on the Continued Investigation of Elacestrant in ER+/HER2– Breast Cancer

November 15th 2023

Aditya Bardia, MD, MPH, discusses the continued investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

October 30th 2023

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Looking Towards The Future of HR+/HER2- Breast Cancer

August 22nd 2023

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.

Practical Considerations for ADC Selection in HR+/HER2- mBC

August 22nd 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

Data Updates on Sacituzumab Govitecan

August 15th 2023

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.

Biomarker Testing Practices in HR+/HER2- Breast Cancer

August 15th 2023

Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.

HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

August 8th 2023

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Addressing Disease Progression on ET: Data Updates and Ongoing Trials

August 8th 2023

A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.

Potential Approaches to Treatment Switching in HR+/HER2- mBC

August 1st 2023

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice

August 1st 2023

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.